Skip to main content
    R

    ResMed Inc (RMD)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $238.23
    -1.30 (-0.54%)

    Market Cap: $33.69B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    ResMed Inc (RMD) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    ResMed (RMD) trades at 20.7x trailing earnings and 5.9x sales. Its P/E of 20.7x is below its 5-year median of 27.8x. Its forward P/E is 20.0x. The median P/E across 11 similar companies is 21.2x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 3.5% higher over the next year. Its free cash flow yield is 4.7%.

    MultipleValue
    P/E (trailing)20.7x
    Forward P/E20.0x
    Price to sales5.9x
    Price to book5.7x
    EV/EBITDA15.3x
    Price to FCF21.2x
    EV/FCF20.8x
    PEG1.3
    FCF yield4.7%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 31.0% below 30.0x, its P/S is 15.7% below 7.0x and its P/B is 23.0% below 7.4x.

    MultipleCurrent5-year median10-year median
    P/E20.7x27.8x30.0x
    P/S5.9x7.2x7.0x
    P/B5.7x6.5x7.4x
    Medians of month-end values through Oct 2026: 59 to 60 months (5-year) and 119 to 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 22.4x in 2016 to 46.3x in 2021.

    Year endPriceP/EP/SP/B
    2025$240.8723.4x6.5x5.6x
    2024$228.6925.9x6.8x6.4x
    2023$172.0225.3x5.6x5.6x
    2022$208.1334.8x8.1x8.2x
    2021$260.4846.3x11.0x12.1x
    2020$212.5640.1x10.0x10.8x
    2019$154.9738.9x8.0x9.9x
    2018$113.8730.9x6.6x8.3x
    2017$84.6927.0x5.5x6.0x
    2016$62.0522.4x4.4x5.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RMD

    What is RMD's forward P/E ratio?

    ResMed has a forward P/E ratio of 20.0x.

    Is RMD stock overvalued?

    GNG's valuation label for RMD is Undervalued. Its P/E of 20.7x compares with a median of 21.2x across 11 similar companies.

    What is RMD's price to sales ratio?

    ResMed has a price to sales ratio of 5.9x.

    What is ResMed's average P/E ratio over 5 years?

    ResMed's median P/E over the last 5 years is 27.8x, from 60 month-end values through Oct 2026.

    What is RMD's PEG ratio?

    ResMed has a PEG ratio of 1.3.